Statements (73)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:legal_case
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Lucentis
|
| gptkbp:aims_to |
effects of statins
|
| gptkbp:applies_to |
public health policies
cardiology field |
| gptkbp:completed |
gptkb:2010
|
| gptkbp:conducted |
academic institutions
multiple countries several years various demographics collaboration of researchers |
| gptkbp:contributed_to |
guidelines for statin use
|
| gptkbp:dosage_form |
gptkb:high-dose_atorvastatin
|
| gptkbp:focuses_on |
statin therapy
|
| gptkbp:followed_by |
subsequent trials on statins
|
| gptkbp:has_impact_on |
clinical practice
|
| https://www.w3.org/2000/01/rdf-schema#label |
ANCHOR trial
|
| gptkbp:is_analyzed_in |
safety and efficacy
clinical outcomes healthcare studies long-term outcomes meta-analysis studies |
| gptkbp:is_associated_with |
improved patient outcomes
|
| gptkbp:is_cited_in |
gptkb:municipality
systematic reviews clinical research articles numerous subsequent studies |
| gptkbp:is_compared_to |
placebo group
|
| gptkbp:is_discussed_in |
gptkb:academic_journal
medical conferences clinical pharmacology health policy debates medical ethics debates clinical guidelines meetings |
| gptkbp:is_evaluated_by |
regulatory agencies
clinical settings cost-effectiveness adverse effects |
| gptkbp:is_influenced_by |
previous studies on statins
|
| gptkbp:is_influential_in |
treatment protocols
|
| gptkbp:is_linked_to |
improved quality of life
improved cardiovascular health reduction in mortality rates |
| gptkbp:is_part_of |
evidence-based medicine
cholesterol lowering initiatives cholesterol treatment research larger research on cholesterol management statin research history |
| gptkbp:is_referenced_in |
medical textbooks
|
| gptkbp:is_related_to |
gptkb:ASCOT_trial
heart disease prevention lipid management strategies |
| gptkbp:is_supported_by |
gptkb:municipality
pharmaceutical companies patient advocacy groups clinical trial networks |
| gptkbp:is_used_for |
reference for future research
|
| gptkbp:is_utilized_in |
medical education
|
| gptkbp:launched |
gptkb:2005
|
| gptkbp:led_to |
gptkb:Dr._Steven_Nissen
|
| gptkbp:outcome |
cardiovascular events
|
| gptkbp:participants |
patients with coronary artery disease
|
| gptkbp:published_by |
gptkb:New_England_Journal_of_Medicine
peer-reviewed journals |
| gptkbp:published_year |
gptkb:2011
|
| gptkbp:receives_funding_from |
gptkb:Research_Institute
|
| gptkbp:registration |
gptkb:Clinical_Trials.gov
|
| gptkbp:reports_to |
gptkb:academic_journal
|
| gptkbp:research_focus |
supporting aggressive lipid lowering
|
| gptkbp:result |
reduction in heart attack risk
|
| gptkbp:sponsor |
gptkb:Pfizer
|
| gptkbp:uses |
gptkb:atorvastatin
|